The root of chronic disease
lives in the gut.
We are building medicines that target inflammation where it begins — guided by the body's own evolutionarily conserved biology.
Why Rasayana exists
Rasayana was founded to give hope to the hundreds of millions living with chronic inflammatory conditions — people who have spent years being managed, not healed.
Behind conditions like IBD, metabolic disease, and autoimmunity lies a common thread: unresolved inflammation that medicine has addressed at the surface, not at the source. We are here to change that.
What we are here to do
Our mission is grounded in science, driven by urgency, and measured by the patients we reach.
"Chronic disease has been treated at the surface for too long."
Rasayana is on a mission to extend human healthspan by targeting gut inflammation — the silent driver behind the world's most devastating chronic conditions. We are not building another symptomatic therapy. We are going to the root.
Our approach is simple: Address the upstream causes of immune dysregulation at the gut mucosal interface, rather than blocking downstream inflammatory signals one cytokine at a time.
This means developing medicines that restore barrier integrity, recalibrate immune activation, and target the bidirectional communication pathways between the gut and distant organs — unlocking therapeutic potential far beyond the GI tract.
We are built for speed, rigor, and impact — because patients do not have time to wait for incremental progress.
We envision a future where chronic inflammatory condition has a precise, gut-informed answer.
The gut-body axis is one of the most powerful and underexplored frontiers in modern medicine. As we build our understanding of its role in systemic inflammation, we see a future using multiomics data from patients, and AI to guide the next generation of precision anti-inflammatory medicines — systematically, at scale, across conditions.
Our Lead Program
We are advancing RSY-248, a first-in-class oral biologic designed to restore immune homeostasis and barrier integrity at the gut mucosal interface.
The Gut-Immune-Organ Axis represents an untapped frontier in drug development. Emerging science reveals that chronic inflammation begins in the gut — where barrier breakdown, dysbiosis, and immune activation create a cascade of pathology that extends to distant organs.
Our therapeutic strategy targets this axis at its origin, addressing the root biological drivers rather than suppressing downstream symptoms.
Phosphatase
Our lead program, RSY-248, is an oral recombinant form of intestinal alkaline phosphatase (IAP) — a naturally occurring enzyme that plays a critical role in maintaining immune balance and gut barrier integrity. RSY-248 acts at the gut mucosal interface through a multimodal mechanism that restores immune and barrier homeostasis.
The Problem We Are Solving
In chronic inflammatory conditions, conventional therapies block single downstream cytokines — leaving the upstream drivers of immune dysregulation intact. This is why patients experience incomplete remission, loss of response over time, and the need for escalating therapies.
RSY-248 takes a fundamentally different approach: addressing the root of immune dysregulation at the mucosal interface, where inflammation originates.
IAP reduces inflammation, upregulates tight junction proteins, reducing "Leaky Gut", and promotes a healthy microbiome.
Why IAP — Evolutionarily Conserved Biology
IAP is an enzyme that has been conserved across hundreds of millions of years of evolution, suggesting a fundamental role in maintaining mucosal homeostasis. Its expression is reduced in chronic inflammatory conditions — making its restoration a physiologically grounded therapeutic strategy.
RSY-248 replenishes what disease depletes, working with the body's own biology rather than against it.
"We believe that restoring gut barrier integrity while inhibiting upstream immune activation may enable more durable disease control in chronic inflammatory conditions — and unlock broader therapeutic potential across the gut–organ axis, including metabolic, neuroinflammatory, and age-associated diseases."
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Rasayana Therapeutics secures licensing rights to SYN-020, a novel oral recombinant intestinal alkaline phosphatase, advancing the company's mission to target gut inflammation across multiple chronic inflammatory conditions.
Read moreThe root of chronic disease
lives in the gut.
We are building medicines that target inflammation where it begins — guided by the body's own evolutionarily conserved biology.
Why Rasayana exists
Rasayana was founded to give hope to the hundreds of millions living with chronic inflammatory conditions — people who have spent years being managed, not healed.
Behind conditions like IBD, metabolic disease, and autoimmunity lies a common thread: unresolved inflammation that medicine has addressed at the surface, not at the source. We are here to change that.
What we are here to do
Our mission is grounded in science, driven by urgency, and measured by the patients we reach.
"Chronic disease has been treated at the surface for too long."
Rasayana is on a mission to extend human healthspan by targeting gut inflammation — the silent driver behind the world's most devastating chronic conditions. We are not building another symptomatic therapy. We are going to the root.
Our approach is simple: Address the upstream causes of immune dysregulation at the gut mucosal interface, rather than blocking downstream inflammatory signals one cytokine at a time.
This means developing medicines that restore barrier integrity, recalibrate immune activation, and target the bidirectional communication pathways between the gut and distant organs — unlocking therapeutic potential far beyond the GI tract.
We are built for speed, rigor, and impact — because patients do not have time to wait for incremental progress.
We envision a future where chronic inflammatory condition has a precise, gut-informed answer.
The gut-body axis is one of the most powerful and underexplored frontiers in modern medicine. As we build our understanding of its role in systemic inflammation, we see a future using multiomics data from patients, and AI to guide the next generation of precision anti-inflammatory medicines — systematically, at scale, across conditions.
Our Lead Program
We are advancing RSY-248, a first-in-class oral biologic designed to restore immune homeostasis and barrier integrity at the gut mucosal interface.
The Gut-Immune-Organ Axis represents an untapped frontier in drug development. Emerging science reveals that chronic inflammation begins in the gut — where barrier breakdown, dysbiosis, and immune activation create a cascade of pathology that extends to distant organs.
Our therapeutic strategy targets this axis at its origin, addressing the root biological drivers rather than suppressing downstream symptoms.
Phosphatase
Our lead program, RSY-248, is an oral recombinant form of intestinal alkaline phosphatase (IAP) — a naturally occurring enzyme that plays a critical role in maintaining immune balance and gut barrier integrity. RSY-248 acts at the gut mucosal interface through a multimodal mechanism that restores immune and barrier homeostasis.
The Problem We Are Solving
In chronic inflammatory conditions, conventional therapies block single downstream cytokines — leaving the upstream drivers of immune dysregulation intact. This is why patients experience incomplete remission, loss of response over time, and the need for escalating therapies.
RSY-248 takes a fundamentally different approach: addressing the root of immune dysregulation at the mucosal interface, where inflammation originates.
IAP reduces inflammation, upregulates tight junction proteins, reducing "Leaky Gut", and promotes a healthy microbiome.
Why IAP — Evolutionarily Conserved Biology
IAP is an enzyme that has been conserved across hundreds of millions of years of evolution, suggesting a fundamental role in maintaining mucosal homeostasis. Its expression is reduced in chronic inflammatory conditions — making its restoration a physiologically grounded therapeutic strategy.
RSY-248 replenishes what disease depletes, working with the body's own biology rather than against it.
"We believe that restoring gut barrier integrity while inhibiting upstream immune activation may enable more durable disease control in chronic inflammatory conditions — and unlock broader therapeutic potential across the gut–organ axis, including metabolic, neuroinflammatory, and age-associated diseases."
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Rasayana Therapeutics secures licensing rights to SYN-020, a novel oral recombinant intestinal alkaline phosphatase, advancing the company's mission to target gut inflammation across multiple chronic inflammatory conditions.
Read more